METHODS, COMPOUNDS, AND COMPOSITIONS FOR TREATING METABOLIC DISORDERS AND DIABETES
First Claim
1. A method for preventing or treating a pancreatic disorder in a subject in need thereof, comprising administering to said subject an effective amount of a compound of the Formula (I):
-
Y—
(CH2)n—
(CH)t—
[CH2Y]m
(I)wherein Y is SO3X or OSO3X independently chosen for each occurrence;
X is a cationic group which independently for each occurrence is hydrogen, lithium, sodium, potassium, calcium, magnesium, trialkylammonium or aluminum;
n is 1, 2, 3 or 4;
t is 0 when m is 1; and
t is 1 when m is 2.
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods, compounds and compositions for preventing or treating a pancreatic disorder, including diabetes mellitus (e.g. type 1 and/or type 2 diabetes). The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for improving or at least stabilizing pancreatic function(s) and for the prevention and/or treatment of metabolic syndrome and its components. The invention further relates to methods, compounds and compositions for the prevention and/or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in patients in need thereof, including diabetic patients.
105 Citations
32 Claims
-
1. A method for preventing or treating a pancreatic disorder in a subject in need thereof, comprising administering to said subject an effective amount of a compound of the Formula (I):
-
Y—
(CH2)n—
(CH)t—
[CH2Y]m
(I)wherein Y is SO3X or OSO3X independently chosen for each occurrence;
X is a cationic group which independently for each occurrence is hydrogen, lithium, sodium, potassium, calcium, magnesium, trialkylammonium or aluminum;
n is 1, 2, 3 or 4;
t is 0 when m is 1; and
t is 1 when m is 2. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 15, 17, 18, 19, 20, 21, 22, 23)
-
-
9. A method for preventing or treating metabolic syndrome in a subject in need thereof, comprising administering to said subject an effective amount of a compound of the Formula (I):
-
Y—
(CH2)n—
(CH)t—
[CH2Y]m
(I)wherein Y is SO3X or OSO3X independently chosen for each occurrence;
X is a cationic group which independently for each occurrence is hydrogen, lithium, sodium, potassium, calcium, magnesium, trialkylammonium or aluminum;
n is 1, 2, 3 or 4;
t is 0 when m is 1; and
t is 1 when m is 2.
-
-
10. A method for preventing or treating diabetes mellitus in a subject in need thereof, comprising administering to said subject an effective amount of a compound of the Formula (I):
-
Y—
(CH2)n—
(CH)t—
[CH2Y]m
(I)wherein Y is SO3X or OSO3X independently chosen for each occurrence;
X is a cationic group which independently for each occurrence is hydrogen, lithium, sodium, potassium, calcium, magnesium, trialkylammonium or aluminum;
n is 1, 2, 3 or 4;
t is 0 when m is 1; and
t is 1 when m is 2. - View Dependent Claims (11, 12, 13, 14, 16)
-
-
24. Use of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof for the prevention or treatment of a pancreatic disorder in a subject in need thereof.
-
25. Use of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof for the prevention or treatment of the metabolic syndrome in a subject in need thereof.
-
26. Use of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof for the prevention or treatment of diabetes mellitus in a subject in need thereof.
-
27. Use of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof for the prevention or treatment of diabetes mellitus with features of metabolic syndrome in a subject in need thereof.
-
28. A method of preventing or decreasing proteinuria in a subject in need thereof, comprising administering to said subject an effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.
-
29. A method of increasing insulin secretion and/or increasing insulin sensitivity in a subject in need thereof, comprising administering to said subject an effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.
-
30. A method of decreasing insulin resistance in a subject in need thereof, comprising administering to said subject an effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.
-
31. A method of decreasing hyperglycemia in a subject in need thereof, comprising administering to said subject an effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.
-
32. A method for delaying the requirement for treating a diabetic patient with insulin by administering an effective amount of 1,3-propanedisulfonic acid.
Specification